HIV Infections
2 competing products in clinical development for HIV Infections.
Pipeline by Phase
Phase 21
Phase 31
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily | Shionogi | Phase 3 | Completed | 40 |
| GW810781 | Shionogi | Phase 2 | Completed | 35 |